Paladin Labs Inc.
TSX : PLB

Paladin Labs Inc.

March 29, 2005 16:00 ET

Paladin appoints Vice-President, Regulatory Affairs, Drug Safety and Medical Services


NEWS RELEASE TRANSMITTED BY CCNMatthews

FOR: PALADIN LABS INC.

TSX SYMBOL: PLB

MARCH 29, 2005 - 16:00 ET

Paladin appoints Vice-President, Regulatory Affairs, Drug Safety and Medical
Services

MONTREAL, March 29 - Paladin Labs Inc. (TSX: PLB), a leading
Canadian specialty pharmaceutical company, today announced the appointment of
Dr. Patrice Larose as Vice-President, Regulatory Affairs, Drug Safety and
Medical Services. Dr. Larose will join Paladin on April 4, 2005.

"Patrice has a wealth of experience in Canadian regulatory affairs. He
will be a valuable addition to our management team as we continue to pursue
opportunities to acquire the Canadian rights to promising late-stage
development products and as we expand our capabilities to internally develop
late-stage, low risk products," said Jonathan Ross Goodman, President and CEO
of Paladin.

Before joining Paladin, Dr. Larose was Vice-President, Regulatory
Affairs, Drug Safety and Medical Services at Schering Canada Inc. Dr. Larose
obtained a Ph.D in Pharmaceutical Sciences from the University of Montreal in
1987 and is a licensed pharmacist.

About Paladin Labs
Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty
pharmaceutical company focused on acquiring or in-licensing innovative
pharmaceutical products for the Canadian market. With this strategy, a focused
national sales team and proven marketing expertise, Paladin has evolved into
one of Canada's leading specialty pharmaceutical companies. Paladin's shares
trade on the Toronto Stock Exchange under the symbol PLB. For more information
about Paladin, please visit the Company's web site at www.paladinlabs.com.

This news release may contain forward-looking statements or predictions.
These statements represent our judgement as of this date and are subject to
risks and uncertainties that could cause actual results or events to differ
materially from those expressed in such forward-looking statements. Potential
risks and uncertainties include, without limitation, those associated with
product development, clinical trials, future revenues and profitability, and
obtaining marketing approval and other factors that are discussed in the
Management Discussion and Analysis published in the Company's annual report.

%SEDAR: 00006013EF


-30-

Contact Information

  • FOR FURTHER INFORMATION PLEASE CONTACT:
    Samira Sakhia
    Chief Financial Officer
    Paladin Labs Inc.
    (514) 340-5067
    info@paladin-labs.com
    Bruce Wigle
    Investor Relations
    The Equicom Group Inc.
    (416) 815-0700 ext. 228
    bwigle@equicomgroup.com